Knee Osteoarthritis Market

 Market Overview:

The 7 major knee osteoarthritis markets reached a value of US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 9.1 Billion by 2034, exhibiting a growth rate (CAGR) of 6.18% during 2024-2034.

The knee osteoarthritis market has been comprehensively analyzed in IMARC's new report titled "Knee Osteoarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Knee osteoarthritis, also referred to as degenerative joint disease, is a condition characterized by the slow deterioration of connective tissues in the knee joint. As the illness progresses, the joint may become inflamed, and bony growths called bone spurs may develop in the affected area. These changes can result in pain, swelling, and difficulty performing daily functions, such as climbing stairs, walking, or bending the knee. The symptoms of the ailment can vary from person to person but commonly include stiffness, grating or popping sensations, reduced range of motion, muscle weakness, instability, etc. The diagnosis of this disorder typically involves a combination of characteristic findings, medical history, and physical examination. The healthcare provider may also perform X-rays to visualize the knee and assess the extent of joint damage. In some cases, numerous other imaging tests, such as computed tomography (CT) scans or magnetic resonance imaging (MRI), may be recommended to obtain more detailed information about the joint structures. Furthermore, an arthrocentesis is conducted to confirm the diagnosis in individuals suffering from the disease. 

The increasing cases of structural abnormalities in the knee joint, such as malalignment or instability that can lead to an uneven distribution of forces across the joint surfaces, causing cartilage damage, are primarily driving the knee osteoarthritis market. In addition to this, the expanding geriatric population, who are prone to degenerative changes due to reduced tissue repair capacity, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapy, owing to its various advantages, like strengthening the muscles around the knee joint, improving flexibility, and offering pain relief to patients, is further bolstering the market growth. Apart from this, the inflating application of assistive devices, including canes, crutches, braces, etc., that help to reduce stress on the joint and provide support during movement is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hyaluronic acid injections, since they improve the viscoelastic properties of the synovial fluid, thereby decreasing friction between the bones, is expected to drive the knee osteoarthritis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the knee osteoarthritis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for knee osteoarthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the knee osteoarthritis market in any manner.

Recent Developments:

• In January 2024, Genascence Corporation announced the start of its Phase 1b clinical trial of GNSC-001 for the treatment of knee osteoarthritis (DONATELLO). The trial is currently enrolling at ten clinical facilities across the United States. The trial will include roughly 50 patients, with enrollment scheduled to be completed in the first quarter of 2024.
• In November 2023, Biosplice Therapeutics, Inc. reported the results of OA-07, a long-term extension study for its knee osteoarthritis medication candidate, lorecivivint. The study's findings support the theory that multiple lorecivivint injections could slow structural progression while also providing symptomatic relief.

Key Highlights:

• Among persons 60 years or older, the prevalence of symptomatic knee osteoarthritis is around 10% in men and 13% in women.
• The annual incidence of knee osteoarthritis is highest in adults between the ages of 55 to 64.
• The global incidence of knee osteoarthritis in adults aged 20 and up is 203 per 10,000 person-years.
• Some risk factors for knee osteoarthritis include being female, obese, or sedentary, and using a Western toilet.
• Knee osteoarthritis is more common in women than men.

Drugs:

ZILRETTA is an extended-release synthetic corticosteroid used as an intra-articular injection to treat osteoarthritis pain in the knee. ZILRETTA is delivered as a single intra-articular extended-release injection of triamcinolone acetonide, delivering 32 mg (5 mL).

Lorecivivint is a potential treatment for knee osteoarthritis being developed by Biosplice Therapeutics. It is a structure-modifying medication that inhibits the activity of CDC-like kinase 2 (CLK2) and DYRK1A. This improves the health and function of chondrocytes and reduces inflammation.

DFV890 is a drug being studied by Novartis for its potential to treat knee osteoarthritis. DFV890 is a small molecule drug that suppresses NLRP3 activation and, thereby, inflammasome assembly. This inhibits the activation of inflammatory interleukins (IL-1β, IL-19) and caspase-1.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the knee osteoarthritis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the knee osteoarthritis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current knee osteoarthritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the knee osteoarthritis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the knee osteoarthritis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the knee osteoarthritis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of knee osteoarthritis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of knee osteoarthritis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of knee osteoarthritis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with knee osteoarthritis across the seven major markets?
• What is the size of the knee osteoarthritis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of knee osteoarthritis?
• What will be the growth rate of patients across the seven major markets?
   

Knee Osteoarthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for knee osteoarthritis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the knee osteoarthritis market?
• What are the key regulatory events related to the knee osteoarthritis market?
• What is the structure of clinical trial landscape by status related to the knee osteoarthritis market?
• What is the structure of clinical trial landscape by phase related to the knee osteoarthritis market?
• What is the structure of clinical trial landscape by route of administration related to the knee osteoarthritis market?